Royal Bank of Canada’s Protara Therapeutics TARA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18K | Sell |
3,500
-989
| -22% | -$5.85K | ﹤0.01% | 5956 |
|
|
2025
Q4 | $25K | Buy |
4,489
+180
| +4% | +$1K | ﹤0.01% | 5927 |
|
|
2025
Q3 | $18K | Sell |
4,309
-21,755
| -83% | -$70.4K | ﹤0.01% | 6255 |
|
|
2025
Q2 | $79K | Buy |
26,064
+22,564
| +645% | +$77.8K | ﹤0.01% | 5731 |
|
|
2025
Q1 | $15K | Hold |
3,500
| – | – | ﹤0.01% | 6028 |
|
|
2024
Q4 | $18K | Hold |
3,500
| – | – | ﹤0.01% | 6152 |
|
|
2024
Q3 | $6K | Sell |
3,500
-2,802
| -44% | -$5.76K | ﹤0.01% | 6470 |
|
|
2024
Q2 | $13K | Buy |
6,302
+2,316
| +58% | +$6.77K | ﹤0.01% | 6253 |
|
|
2024
Q1 | $16K | Buy |
3,986
+3,258
| +448% | +$10.5K | ﹤0.01% | 6017 |
|
|
2023
Q4 | $1K | Buy |
728
+228
| +46% | +$336 | ﹤0.01% | 6984 |
|
|
2023
Q3 | $1K | Sell |
500
-2,920
| -85% | -$6.69K | ﹤0.01% | 6938 |
|
|
2023
Q2 | $8K | Buy |
3,420
+3,320
| +3,320% | +$9.86K | ﹤0.01% | 6554 |
|
|
2023
Q1 | $0 | Hold |
100
| – | – | ﹤0.01% | 7465 |
|
|
2022
Q4 | $0 | Hold |
100
| – | – | ﹤0.01% | 7703 |
|
|
2022
Q3 | $0 | Hold |
100
| – | – | ﹤0.01% | 7851 |
|
|
2022
Q2 | $0 | Sell |
100
-46
| -32% | -$168 | ﹤0.01% | 7704 |
|
|
2022
Q1 | $1K | Sell |
146
-13
| -8% | -$68 | ﹤0.01% | 7622 |
|
|
2021
Q4 | $1K | Sell |
159
-505
| -76% | -$3.48K | ﹤0.01% | 7534 |
|
|
2021
Q3 | $4K | Sell |
664
-290
| -30% | -$2.26K | ﹤0.01% | 7208 |
|
|
2021
Q2 | $9K | Sell |
954
-15
| -2% | -$170 | ﹤0.01% | 6918 |
|
|
2021
Q1 | $15K | Buy |
969
+369
| +62% | +$6.84K | ﹤0.01% | 6606 |
|
|
2020
Q4 | $15K | Sell |
600
-157
| -21% | -$3.38K | ﹤0.01% | 6205 |
|
|
2020
Q3 | $13K | Buy |
757
+157
| +26% | +$3.64K | ﹤0.01% | 5855 |
|
|
2020
Q2 | $18K | Hold |
600
| – | – | ﹤0.01% | 5637 |
|
|
2020
Q1 | $14K | Buy |
+600
| New | +$17.5K | ﹤0.01% | 5705 |
|
|
2019
Q1 | – | Sell |
-110
| Closed | -$10K | – | 7092 |
|
|
2018
Q4 | $10K | Buy |
110
+14
| +15% | +$989 | ﹤0.01% | 5899 |
|
|
2018
Q3 | $7K | Hold |
96
| – | – | ﹤0.01% | 6124 |
|
|
2018
Q2 | $9K | Hold |
96
| – | – | ﹤0.01% | 5860 |
|
|
2018
Q1 | $10K | Hold |
96
| – | – | ﹤0.01% | 5724 |
|
|
2017
Q4 | $7K | Buy |
96
+12
| +14% | +$962 | ﹤0.01% | 5992 |
|
|
2017
Q3 | $7K | Sell |
84
-65
| -44% | -$3.72K | ﹤0.01% | 6364 |
|
|
2017
Q2 | $9K | Sell |
149
-71
| -32% | -$3.98K | ﹤0.01% | 5848 |
|
|
2017
Q1 | $15K | Sell |
220
-82
| -27% | -$6.13K | ﹤0.01% | 5776 |
|
|
2016
Q4 | $23K | Buy |
302
+286
| +1,788% | +$90.5K | ﹤0.01% | 5696 |
|
|
2016
Q3 | $6K | Buy |
+16
| New | +$5.63K | ﹤0.01% | 5928 |
|
|
2015
Q4 | – | Sell |
-19
| Closed | -$11K | – | 6811 |
|
|
2015
Q3 | $11K | Buy |
19
+7
| +58% | +$4.33K | ﹤0.01% | 5851 |
|
|
2015
Q2 | $8K | Buy |
+12
| New | +$7.42K | ﹤0.01% | 6131 |
|
Other funds holding TARA
VCIM
VCM
SCM
ACA
IHAM
ACM
Royal Bank of Canada's TARA Position: Q1 2026 in Review
Royal Bank of Canada reduced its Protara Therapeutics (TARA) stake by 22% in Q1 2026, selling an estimated $5.85K and leaving 3,500 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #5956.
Royal Bank of Canada first reported a position in TARA in Q2 2015 and has held it in 37 quarters since. The position peaked at $79K in Q2 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.
- Royal Bank of Canada held 3,500 shares of Protara Therapeutics worth $18K as of Q1 2026.
- Royal Bank of Canada sold 989 Protara Therapeutics shares in Q1 2026, an estimated $5.85K.
- Protara Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5956 holding.
- Royal Bank of Canada first reported a position in Protara Therapeutics in Q2 2015 and has held it in 37 quarters since.
- Royal Bank of Canada's Protara Therapeutics position peaked at $79K in Q2 2025.
- 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.